Case studies were also presented on two patients with relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) who were treated with ADCETRIS. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
Patients treated in the trial receive 1.8mg/kg of ADCETRIS every three weeks for up to a maximum of eight doses.
Patients who achieve partial remission or stable disease are eligible to receive an additional eight doses.
Study has found that eleven of 17 evaluable patients (65%) achieved an objective response, including seven complete remissions (CRs) and four partial remissions (PRs).
Six patients had stable disease. These investigator-assessed responses were observed in all three subtypes of CTCL.
In the PTCL case studies, PTCL-NOS is associated with a poor prognosis and there is no well-established standard of care, the study authors reported.
The first patient has achieved a PR with progression-free survival of eight months and overall survival of 22 months.
The second patient has achieved a CR which is still ongoing with a duration of more than 19 months.